Smith & Nephew plc (ADR) (SNN)

sk8jeff1 (86.80) Submitted: 5/23/2009 9:53:06 AM : Start Price: $35.59 SNN Score: +8.43

Smith and Nephew is a large and safe company. SNN is near a 52 week low. Nothing about SNN itself has caused this drop in stock price. The costs of lending, oil prices and the generally poor economy have caused this stock to drop. SNN has a couple of new products in the final stages of development that will be used by orthopedic surgeons within the next year.SNN is widely regarded in the medical community for making safe, reliable and innovative products. They consult with and are counseled by physicians in Boston when making these products. There is no reason to believe their new products will not be just as successful as their past products. Get this stock near its 52 week low. It will pay you dividends and the price will grow.

ipfmanager (98.28) Submitted: 2/25/2009 3:52:34 PM : Start Price: $32.62 SNN Score: +12.50

I'm the top scorer on this? Sheesh....

Let's see... Check my myl pitch-similar line of reasoning. Plus it's an adr for all those anti-americans out there. I actually like Striker or Zimmer better.

ddberg (97.74) Submitted: 1/28/2009 11:07:43 AM : Start Price: $35.24 SNN Score: +6.33

Aging population that's living longer, exponential growth in orthopedic procedures, and a strong presence in those operating rooms.

9ballkid (< 20) Submitted: 9/12/2008 8:44:15 PM : Start Price: $54.12 SNN Score: -4.86

low debt nice holder for long time 34.00 pay out precentage room to buy more stock back

nbpt100 (32.82) Submitted: 7/29/2008 12:59:50 PM : Start Price: $53.17 SNN Score: -0.71

Yes SNN will outperform the S&P 500 but don't expect huge returns. On the other hand the downward potential is not that much. It is a good investment based on the risk return ratio. This is a conservative company with a 1% dividend. Most of their profit comes from disposible medical devices which is a strong and steady business but slow single digit growth. Their wound management business is a very slow grower and I would not be surprised if they sold it. The big growth is in the orthapedics area which should deliver double digit growth. That is what everyone is focused on. The Stock price took a big hit earlier this year because of an impropropriety in Greece. The company has been buying back stock which does help the shareholders. Once they get over this impropriety in Greece the stock should return to outperforming the market, but don't expect a double in 2 years. This is a good investment for a more risk averse individual. It is a buy at todays prices.

WOODYHAZE (< 20) Submitted: 7/9/2008 10:39:13 AM : Start Price: $53.35 SNN Score: +0.29

Following Mad Money on this one...

Jstaple7 (< 20) Submitted: 2/26/2008 4:53:29 PM : Start Price: $64.07 SNN Score: -8.71

Great growth stock as the ortho company has increased market share each year. They continue to pressure leading competitors Zimmer and Stryker and are poised to overtake Zimmer in 2010.

They have addressed their inventory concerns from 2006 and are continuing to implement full lean processes. The SAP conversion from previously outdated BPCS will only aid in the management of their inventories.

korhonen (84.92) Submitted: 11/1/2007 2:49:23 PM : Start Price: $62.33 SNN Score: +1.01

SNN has exceeded earnings estimates for the past four quarters (but not in today's earnings report) This quarter's earnings downturn reflects a short-term "slump" but projected growth is expected to remain strong. Fundamentals are still strong.

TrackMasterTrack (28.31) Submitted: 10/11/2007 2:27:44 AM : Start Price: $60.71 SNN Score: +5.23

bound to out pace

Bizoid (47.93) Submitted: 6/19/2007 11:16:42 AM : Start Price: $59.65 SNN Score: +4.30

I like joints.

NetscribeMedDevs (88.12) Submitted: 3/21/2007 8:49:26 AM : Start Price: $61.04 SNN Score: -4.13

Smith & Nephew develops and markets advanced medical devices for orthopedics, endoscopy, and wound management sectors worldwide. The company operates thorough its Global Business Units which include Orthopaedic Reconstruction, Orthopaedic Trauma & Clinical Therapies, Endoscopy and Advanced Wound Management. Through these business units and a separate indirect market unit the compene operates in 33 countries around the world.

The total revenues grew by 15% for the fourth quarter of the fiscal 2006 as compared to the same period in 2005. The company is a market leader in providing innovative products especially in reconstruction. The slate of new products the company introduced last year, plus the additions this year, gives it a strong platform for growth. Products like BHR and JOURNEY were only introduced halfway through the year, so it is expected to benefit for the full-year 2007.

The company is looking forward to seek value enhancing acquisitions that relate to unique or additive technologies and products and to improve its channels to market. In line with this strategy the company has recently acquired Plus Orthopedics. Plus is one of the top players in hips in Germany which is the world’s third largest orthopedics market and they also are a strong player in knees in Germany as well and their manufacturing is based both in Switzerland and in China. This acquisition is expected to strengthen the company’s distribution channels and increase leverage in its sales channels both in Europe and Asia.

Looking at the company’s market leadership in all of its business units and its strategy to break into new markets will help the company grow in a rapid pace. It is expected that this will not only make the company’s performance strong but also help the stockholders reap maximum profits out of their holdings.

momoose1 (96.03) Submitted: 1/13/2007 12:58:55 PM : Start Price: $51.45 SNN Score: +11.19

continues to be the fastest growing ortho recon company. ahead of the competition with hip resurfacing product and alternate bearings for both hips & knees.

phdche (50.91) Submitted: 12/22/2006 7:28:10 AM : Start Price: $50.60 SNN Score: +11.94

Potential for buy out by private firm

ROXYMUSIC1 (88.08) Submitted: 12/6/2006 8:34:52 PM : Start Price: $45.80 SNN Score: +22.02

UK based company that engages in the development and manufacture of medical devices and equipment for hip, knee, and shoulder joint replacement. Excellent run company. Nice earnings. Recommended.